BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27698402)

  • 1. Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.
    Novillo A; Romero-Lorca A; Gaibar M; Rubio M; Fernández-Santander A
    Pharmacogenomics J; 2017 Mar; 17(2):109-111. PubMed ID: 27698402
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.
    Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Suc E; Sillet-Bach I; Filleron T; Roché H; Chatelut E; White-Koning M; Thomas F
    Clin Pharmacol Ther; 2019 Sep; 106(3):585-595. PubMed ID: 30786012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
    Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
    Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
    Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
    Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
    Safgren SL; Suman VJ; Kosel ML; Gilbert JA; Buhrow SA; Black JL; Northfelt DW; Modak AS; Rosen D; Ingle JN; Ames MM; Reid JM; Goetz MP
    Pharmacogenet Genomics; 2015 Apr; 25(4):157-63. PubMed ID: 25714002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 and tamoxifen: awaiting the denouement.
    Brauch HB; Schroth W; Ingle JN; Goetz MP
    J Clin Oncol; 2011 Dec; 29(34):4589-90; author reply 4590-1. PubMed ID: 22042960
    [No Abstract]   [Full Text] [Related]  

  • 9. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
    Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
    Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Tamura K; Imamura CK; Takano T; Saji S; Yamanaka T; Yonemori K; Takahashi M; Tsurutani J; Nishimura R; Sato K; Kitani A; Ueno NT; Mushiroda T; Kubo M; Fujiwara Y; Tanigawara Y
    J Clin Oncol; 2020 Feb; 38(6):558-566. PubMed ID: 31821071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of tamoxifen and irinotecan therapies.
    Algeciras-Schimnich A; O'Kane DJ; Snozek CL
    Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized tamoxifen: what is the best way forward?
    Rae JM
    J Clin Oncol; 2011 Aug; 29(24):3206-8. PubMed ID: 21768456
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
    Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
    Gjerde J; Hauglid M; Breilid H; Lundgren S; Varhaug JE; Kisanga ER; Mellgren G; Steen VM; Lien EA
    Ann Oncol; 2008 Jan; 19(1):56-61. PubMed ID: 17947222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
    Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
    Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.
    Khan BA; Robinson R; Fohner AE; Muzquiz LI; Schilling BD; Beans JA; Olnes MJ; Trawicki L; Frydenlund H; Laukes C; Beatty P; Phillips B; Nickerson D; Howlett K; Dillard DA; Thornton TA; Thummel KE; Woodahl EL
    Clin Transl Sci; 2018 May; 11(3):312-321. PubMed ID: 29436156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 pharmacogenomics of tamoxifen treatment.
    ; ;
    Technol Eval Cent Assess Program Exec Summ; 2014 Jan; 28(8):1-4. PubMed ID: 24730084
    [No Abstract]   [Full Text] [Related]  

  • 19. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PharmGKB summary: tamoxifen pathway, pharmacokinetics.
    Klein DJ; Thorn CF; Desta Z; Flockhart DA; Altman RB; Klein TE
    Pharmacogenet Genomics; 2013 Nov; 23(11):643-7. PubMed ID: 23962908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.